Standard BioTools Inc.
LAB
$1.07
-$0.045-4.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 19.04% | -72.29% | -28.29% | -168.30% | -90.92% |
| Total Depreciation and Amortization | -19.70% | 1.20% | -33.56% | 432.81% | 502.55% |
| Total Amortization of Deferred Charges | -- | -- | 55.16% | -119.46% | -- |
| Total Other Non-Cash Items | 155.12% | 83.89% | 21.05% | 49.31% | -400.37% |
| Change in Net Operating Assets | 30.68% | 412.35% | -1,574.34% | -714.78% | -6,297.80% |
| Cash from Operations | 51.53% | 0.01% | -144.21% | -318.59% | -636.31% |
| Capital Expenditure | -547.12% | -4,235.90% | -149.17% | -131.15% | 22.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -49.31% | 333.86% | 41.60% | 27.41% | -12.09% |
| Cash from Investing | -95.40% | 296.13% | 38.14% | 25.25% | 637.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -4,300.00% | 100.00% | -- | -- |
| Issuance of Common Stock | -- | 24.70% | -15.00% | 330.98% | -- |
| Repurchase of Common Stock | 99.58% | 74.14% | 82.97% | -1,135.10% | -332.68% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 99.77% | -5,335.69% | 99.83% | -1,260.89% | -671.42% |
| Foreign Exchange rate Adjustments | 1,800.00% | -216.09% | -177.55% | -23.61% | -191.30% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -106.51% | -54.27% | 5.57% | -160.21% | 633.94% |